The control group for all regions also includes a small subset of unaffected Leucine-rich repeat kinase 2 (LRRK2) positive samples and individuals with microscopic Alzheimer’s disease lesions that were insufficient for diagnosis. The gene discussed is LRRK2; the disease is early-onset autosomal dominant Alzheimer disease.